CollaGenex Pharmaceuticals (CGPI) Reports Q4 EPS of $0.02
More News related to CGPI
- CollaGenex Pharmaceuticals (CGPI) Reports Q4 EPS of $0.02
- Caxton Associates Discloses 6.1% Stake in CollaGenex (CGPI)
- Roth Capital Downgrades CollaGenex (CGPI) to Hold
- Wachovia Downgrades CollaGenex (CGPI) to Market Perform
- Rodman & Renshaw Downgrades CollaGenex (CGPI) to Market Perform
CollaGenex Pharmaceuticals Inc. (Nasdaq: CGPI) reports Q4 earnings of $0.02 per share, below the consensus of a $0.18 loss. Revenues came in at $17 million, versus the consensus of $15.2 million.
CollaGenex Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets proprietary medical therapies to the dermatology market.
Related Categories
EarningsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
